United States v. Jeremy Donagal ( 2022 )


Menu:
  •                            NOT FOR PUBLICATION                           FILED
    UNITED STATES COURT OF APPEALS                       MAY 20 2022
    MOLLY C. DWYER, CLERK
    U.S. COURT OF APPEALS
    FOR THE NINTH CIRCUIT
    UNITED STATES OF AMERICA,                       No.    21-10169
    Plaintiff-Appellee,             D.C. Nos.
    4:20-cr-00250-JST-1
    v.                                             4:20-cr-00250-JST
    JEREMY DONAGAL,
    MEMORANDUM*
    Defendant-Appellant.
    Appeal from the United States District Court
    for the Northern District of California
    Jon S. Tigar, District Judge, Presiding
    Argued and Submitted May 12, 2022
    San Francisco, California
    Before: WALLACE, W. FLETCHER, and SANCHEZ, Circuit Judges.
    Jeremy Donagal appeals from the sentence imposed as a consequence of his
    conviction for violating 
    21 U.S.C. § 843
    (a)(5), possession of punches or dies for
    the purpose of manufacturing counterfeit drugs, and 
    21 U.S.C. § 331
    (i)(3), the
    doing of any act which caused a drug to be a counterfeit drug. He was sentenced
    to concurrent terms of 27 months’ imprisonment for each count, and a consecutive
    *
    This disposition is not appropriate for publication and is not precedent
    except as provided by Ninth Circuit Rule 36-3.
    10-month term for violating the conditions of supervised release from a prior drug
    conviction.
    On appeal, Donagal contends that the district court erred in calculating his
    base offense level under U.S. Sentencing Guidelines (USSG) § 2D1.12(a)(1) and
    in applying a two-level sentencing enhancement for the supervision of a criminal
    participant under USSG § 3B1.1(c). Because Donagal did not object at sentencing,
    we review his claims for plain error. United States v. Randall, 
    162 F.3d 557
    , 561
    (9th Cir. 1998). We have jurisdiction under 
    28 U.S.C. § 1291
    , and we affirm.
    Where, as here, a defendant is convicted of a felony for which no sentencing
    guideline directly applies, the district court must apply the most analogous
    sentencing guideline. See U.S.S.G § 2X5.1. The district court applied USSG §
    2D1.12(a)(1), a base offense level pertaining to a defendant who “intended to
    manufacture a controlled substance or knew or believed that the prohibited flask,
    equipment, chemical, product, or material was to be used to manufacture a
    controlled substance.” Donagal contends that the court should have applied the
    lesser base offense level under § 2D1.12(a)(2), which requires that a defendant
    have “reasonable cause to believe” the prohibited equipment was to be used to
    manufacture controlled substances. He argues that because there is no evidence he
    intended to manufacture a controlled substance—only a counterfeit substance—it
    was plain error for the court to apply the more severe punishment. We disagree.
    2
    Both USSG §§ 2D1.12(a)(1) and (a)(2) refer to the manufacture of “controlled
    substances” and differ only with respect to a defendant’s mental state. The district
    court did not plainly err in applying USSG § 2D1.12(a)(1) because an “intent to
    manufacture” is more analogous to the circumstances of his case and his plea
    admissions.
    Donagal also challenges the district court’s adoption of a two-level offense
    increase for supervision of a criminal participant. See USSG § 3B1.1(c). Donagal
    contends there was no evidence that his employee was aware of the criminal nature
    of Donagal’s activities to support imposition of the enhancement. See United
    States v. Cyphers, 
    130 F.3d 1361
    , 1363 (9th Cir. 1997) (“[U]nknowing facilitators
    of crimes will not be considered criminally responsible participants.”). The district
    court adopted the factual findings in the Presentence Report without objection, see
    Fed. R. Crim. P. 32(i)(3)(A), which stated that Donagal’s employee had assisted in
    packaging and shipping counterfeit drugs seized from Donagal’s leased warehouse.
    The record reveals a counterfeit drug operation involving an active pill press,
    clandestine laboratory, tens of thousands of finished pills stamped with the
    commercial label for Xanax, and business cards listing a private site on the darknet
    for purchase of these substances. Given the context surrounding the employee’s
    workplace environment and the stringent plain error standard of review, we
    conclude that the district court did not plainly err in imposing this upward
    3
    enhancement.
    JUDGMENT AFFIRMED.
    4
    

Document Info

Docket Number: 21-10169

Filed Date: 5/20/2022

Precedential Status: Non-Precedential

Modified Date: 5/20/2022